Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 62Other hematologic neoplasm 52Myeloid 17Sarcoma 9Plasma cell 6Breast 6Genitourinary 5Classical hematology 5Dermatologic 4Gastrointestinal 2CNS 2Other neoplasm 1Other 1Gynecologic 1

Conditions

Unrecognized Condition: Mature B or T-cell Neoplasm 1

Interventions

Oxycodone 2tremelimumab 1penpulimab 1peginterferon alfa-2b 1Zoledronic Acid 1Zidovudine 1Whole-Body Irradiation 1Valproic Acid 1Tetradecanoylphorbol Acetate 1Surveys and Questionnaires 1Sodium Chloride 1Selenium 1Rosuvastatin Calcium 1Rituximab 1Ribavirin 1Radiosurgery 1Proflavine 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Observation 1Moxifloxacin 1Morphine 1Microarray Analysis 1Methotrexate 1Methadone 1Laser Therapy 1Interferon alpha-2 1Infliximab 1Gene Expression Profiling 1Gadolinium DTPA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Methotrexate × Other neoplasm × Clear all
NCT02701517 2017-12-29

Cyclosporine Plus Methotrexate or Alemtuzumab

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2 Terminated
72 enrolled
LymphoidOther neoplasm

Unrecognized Condition: Mature B or T-cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡